A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi^™, ENF) plus binimetinib (Mektovi^®, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Patient...

Description complète

Détails bibliographiques

Auteurs principaux:	Mohamed M. Hefnawy, Mohammed M. Alanazi, Abdullah M. Al-Hossaini, Abdulaziz I. Alnasser, Adel S. El-Azab, Yousef A. Bin Jardan, Mohamed W. Attwa, Manal A. El-Gendy
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2022-12-01
Collection:	Molecules
Sujets:	LC–MS/MS melanoma encorafenib binimetinib rat plasma pharmacokinetics
Accès en ligne:	https://www.mdpi.com/1420-3049/28/1/79
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!